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Bose SJ, Bijvelds MJC, Wang Y, Liu J, Cai Z, Bot AGM, de
Jonge HR, Sheppard DN. Differential thermostability and response
to cystic fibrosis transmembrane conductance regulator potentiators of
human and mouse F508del-CFTR. Am J Physiol Lung Cell Mol
Physiol 317: L71–L86, 2019. First published April 10, 2019; doi:
10.1152/ajplung.00034.2019.—Cross-species comparative studies
have highlighted differences between human and mouse cystic fibro-
sis transmembrane conductance regulator (CFTR), the epithelial Cl
channel defective in cystic fibrosis (CF). Here, we compare the impact
of the most common CF mutation F508del on the function of human
and mouse CFTR heterologously expressed in mammalian cells and
their response to CFTR modulators using the iodide efflux and
patch-clamp techniques. Once delivered to the plasma membrane,
human F508del-CFTR exhibited a severe gating defect characterized
by infrequent channel openings and was thermally unstable, deacti-
vating within minutes at 37°C. By contrast, the F508del mutation was
without effect on the gating pattern of mouse CFTR, and channel
activity demonstrated thermostability at 37°C. Strikingly, at all con-
centrations tested, the clinically approved CFTR potentiator ivacaftor
was without effect on the mouse F508del-CFTR Cl channel. More-
over, eight CFTR potentiators, including ivacaftor, failed to generate
CFTR-mediated iodide efflux from CHO cells expressing mouse
F508del-CFTR. However, they all produced CFTR-mediated iodide
efflux with human F508del-CFTR-expressing CHO cells, while fif-
teen CFTR correctors rescued the plasma membrane expression of
both human and mouse F508del-CFTR. Interestingly, the CFTR
potentiator genistein enhanced CFTR-mediated iodide efflux from
CHO cells expressing either human or mouse F508del-CFTR,
whereas it only potentiated human F508del-CFTR Cl channels in
cell-free membrane patches, suggesting that its action on mouse
F508del-CFTR is indirect. Thus, the F508del mutation has distinct
effects on human and mouse CFTR Cl channels.
CFTR chloride ion channel; CFTR potentiation; cystic fibrosis;
F508del-CFTR; ivacaftor (VX-770)
INTRODUCTION
The most frequent cause of the life-limiting genetic disease
cystic fibrosis (CF) is the F508del mutation in the cystic
fibrosis transmembrane conductance regulator (CFTR) (23, 62,
63). CFTR is an ATP-binding cassette (ABC) transporter
(ABCC7) (37), which functions as an ATP-gated anion chan-
nel regulated by cAMP-dependent phosphorylation (40). Lo-
cated in the apical membrane of epithelia-lining ducts and
tubes, it plays a key role in the regulation of transepithelial
fluid and electrolyte movement (6, 68). Deletion of F508
causes a temperature-sensitive folding defect, which disrupts
CFTR processing and intracellular transport to the plasma
membrane (16, 26). But, in addition, the mutation destabilizes
any CFTR protein that reaches the plasma membrane and
interferes with channel gating, reducing greatly the frequency
of channel opening (24, 48). To overcome these defects in
F508del-CFTR, orally bioavailable small molecules termed
CFTR correctors and potentiators have been developed (34, 43,
52). CFTR correctors repair misfolding of nucleotide-binding
domain 1 (NBD1) and facilitate correct domain assembly,
leading to the plasma membrane expression of F508del-CFTR
protein (29, 53, 83). By contrast, CFTR potentiators increase
the frequency and duration of channel openings to restore
channel activity to F508del-CFTR (28, 41, 82). Additional
beneficial actions of CFTR modulators include dampening
inflammatory responses in CF airway epithelia (67) and restor-
ing bacterial killing to CF macrophages (4).
To understand how the F508del mutation causes organ-level
disease and assist the evaluation of innovative CF therapeutics,
F508del-CFTR mouse models have been developed (19, 81,
95). Studies of these and other mouse models have highlighted
differences in the pathophysiology of CF between humans and
mice (for review, see Ref. 92). In part, these differences are
explained by the distinct anatomy and physiology of humans
and mice, which include variation in the expression of ion
channels and transporters between the two species. For exam-
ple, altered expression of the calcium-activated Cl channel
TMEM16A might protect CF mice from pancreatic disease
(18, 56), whereas the absence of the nongastric H,K-AT-
Pase ATP12A might defend CF mice from lung infection (74).
Interestingly, several lines of evidence suggest that differences
in CFTR expression, structure, and function might also con-
tribute to the distinct presentation of CF in humans and mice.
First, the amino acid sequence of mouse CFTR differs notice-
ably from that of human CFTR (shared amino acid identity,
79%), exhibiting a higher degree of variation than that pre-
dicted by the phylogenetic tree (9, 79). Second, the F508del
processing defect is less severe for mouse than for human
CFTR (55). Third, there are striking differences in single-
channel behavior between human and mouse CFTR (46, 72).
Finally, mouse CFTR appears unresponsive to some but not all
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CFTR modulators (45, 64), while conflicting results have been
obtained with the CFTR potentiator ivacaftor (20–22, 82, 96).
In this study, we investigated the impact of the F508del
mutation on mouse CFTR. Using CHO cells heterologously
expressing mouse F508del-CFTR and the patch-clamp and
iodide efflux techniques, we studied its single-channel behav-
ior, thermostability, and rescue by CFTR modulators. In
marked contrast to the mutation’s severe impact on human
CFTR, F508del was without effect on the gating behavior of
mouse CFTR and its stability in cell-free membrane patches at
37°C. Similarly, most CFTR potentiators, including ivacaftor,
failed to augment the activity of mouse F508del-CFTR,
whereas CFTR correctors, including lumacaftor, rescued both
human and mouse F508del-CFTR. Thus, subtle changes in
protein structure influence the action of the F508del mutation
on CFTR function and the effects of CFTR potentiators.
METHODS
Cells and cell culture. We used Chinese hamster ovary (CHO-K1)
cells stably expressing human and mouse wild-type and F508del-
CFTR (45). Because single-channel recording was not feasible with
CHO cells expressing human F508del-CFTR (Bose SJ, Cai Z, and
Sheppard DN, unpublished observations), we used NIH-3T3 cells and
BHK cells stably expressing human wild-type and F508del-CFTR for
patch-clamp studies (7, 30). Cells were generous gifts of J. R. Riordan
(human CFTR-expressing CHO cells; University of North Carolina),
B. J. Wainwright (mouse CFTR-expressing CHO cells; University of
Queensland), M. D. Amaral (human CFTR-expressing BHK cells;
University of Lisboa), and M. J. Welsh (human CFTR-expressing
NIH 3T3 cells; University of Iowa). CHO cells were cultured in
Ham’s F-12 nutrient medium supplemented with 10% fetal bovine
serum (FBS), 100 U/ml penicillin, 100 g/ml streptomycin, and either
200 g/ml neomycin (mouse wild-type CFTR) or 220 g/ml metho-
trexate (mouse F508del-CFTR). BHK cells were cultured as previ-
ously described (70), while NIH-3T3 cells were cultured in Dulbec-
co’s modified Eagle’s medium supplemented with 10% FBS, 100
U/ml penicillin, 100 g/ml streptomycin, and 380 g/ml G418
(F508del-CFTR-expressing NIH-3T3 cells only). All cells were cul-
tured at 37°C in a humidified atmosphere containing 5% CO2. For
patch-clamp experiments, cells were seeded onto glass coverslips and
used within 7 days, with the media changed every 2 days. For 125I
efflux experiments, cells were grown as monolayers to 70–80%
confluence in tissue culture-treated six-well cell culture plates. To
rescue the plasma membrane expression of F508del-CFTR, cells were
incubated at 26–27°C for 24–96 h (26) or treated with lumacaftor (3
M) for 24–48 h at 37°C (83). The single-channel behavior of human
CFTR in excised membrane patches from different mammalian cell
lines is equivalent [wild-type CFTR (15); F508del-CFTR: BHK cells,
i  0.72 0.01 pA, Po  0.07 0.01, n  20; C127 cells, i 
–0.78  0.02 pA, Po  0.06 0.01, n  12 using the conditions
described in Fig. 1]. Previous work (46, 55) also suggests that the
single-channel properties of mouse CFTR are comparable using
different mammalian cells.
Iodide efflux experiments. Monolayers of CHO cells expressing
human and mouse wild-type and F508del-CFTR were loaded with
125I for 2 h under a humidified atmosphere of O2/CO2 (19:1) at 37°C
in 0.5 ml of isotonic medium containing (in mM) 130 NaCl, 5 KCl,
1.3 CaCl2, 1 MgCl2, 10 glucose, and 20 HEPES (pH 7.40) and 5
Ci/ml 125I. Then, extracellular 125I was removed within 1 min by
washing the cells three times with 3 ml of isotonic medium (without
125I) at room temperature. Efflux of 125I was measured at 37°C by
addition and consecutive removal of 1 ml of the isotonic medium
without 125I at 1- to 2-min intervals. At the end of the experiment,
residual 125I was determined by collecting the cells in 1 ml of 1 M
NaOH. The amount of 125I in the collected samples of isotonic
medium was determined by -radiation counting and expressed as
fractional efflux per minute, as described previously (80). For studies
of CFTR correctors, CHO cells heterologously expressing CFTR were
pretreated with small molecules for 26 h at 37°C before experiments
were commenced, whereas forskolin and CFTR potentiators were
added to the isotonic medium bathing cells from 3 min after sample
collection was initiated until the end of the experiments.
Patch-clamp experiments. CFTR Cl channels were recorded in
excised inside-out membrane patches using Axopatch 200A and 200B
patch-clamp amplifiers and pCLAMP software (versions 6.0 and 10.3;
all from Molecular Devices, San Jose, CA), as described previously
(75). The pipette (extracellular) solution contained (in mM) 140
N-methyl-D-glucamine (NMDG), 140 aspartic acid, 5 CaCl2, 2
MgSO4, and 10 N-tris[hydroxymethyl]methyl-2-aminoethanesul-
phonic acid (TES), adjusted to pH 7.3 with Tris ([Cl]; 10 mM). The
bath (intracellular) solution contained (in mM) 140 NMDG, 3 MgCl2,
1 CsEGTA, and 10 TES, adjusted to pH 7.3 with HCl ([Cl], 147
mM; free [Ca2], 108 M). Using a temperature-controlled micro-
scope stage (Brook Industries, Lake Villa, IL), the temperature of the
bath solution was varied between 23 and 37°C.
After excision of inside-out membrane patches, we added the
catalytic subunit of protein kinase A (PKA; 75 nM) and ATP (1 mM)
to the intracellular solution within 5 min of membrane patch excision
to activate CFTR Cl channels. To minimize channel rundown, we
added PKA (75 nM) and ATP (1 mM) to all intracellular solutions and
clamped voltage at –50 mV. The effects of temperature on the
single-channel behavior of mouse CFTR were tested by increasing the
temperature of the intracellular solution from 23 to 37°C in incre-
ments of 3–4°C (90). Once channel activity stabilized at the new test
temperature, we acquired 4–10 min of single-channel data before
increasing further the temperature and repeating the acquisition of
data.
To investigate the plasma membrane stability of mouse F508del-
CFTR, we monitored its thermal stability in excised inside-out mem-
brane patches at 37°C (91). Membrane patches were excised at 27°C,
and mouse F508del-CFTR Cl channels were activated by the addi-
tion of PKA (75 nM) and ATP (1 mM) to the intracellular solution.
Once channels were fully activated, the temperature of the intracel-
lular solution was increased rapidly to 37°C. To evaluate thermal
stability, we calculated open probability (Po) values in 30-s intervals
over a 10-min period commencing when the temperature reached
37°C (91). To test the actions of ivacaftor and genistein on mouse
wild-type and F508del-CFTR, the CFTR potentiators were added to
the intracellular solution in the continuous presence of ATP (1 mM)
and PKA (75 nM). Because of the difficulty of removing ivacaftor
from the recording chamber (91), specific interventions were com-
pared with the preintervention control period made with the same
concentrations of ATP and PKA, but without the test CFTR potenti-
ator.
In this study, we used excised inside-out membrane patches con-
taining up to five active channels [human wild-type CFTR, number of
active channels (n)  5; human F508del-CFTR, n  5; mouse
wild-type CFTR, n  4; mouse F508del-CFTR, n  3). To determine
channel number, we used the maximum number of simultaneous
channel openings observed during an experiment (13). To minimize
errors, we used experimental conditions that robustly potentiate chan-
nel activity and verified that recordings were of sufficient length to
ascertain the correct number of channels (85). Despite our precau-
tions, we cannot exclude the possibility of unobserved F508del-CFTR
Cl channels in excised membrane patches. Therefore, Po values for
F508del-CFTR might possibly be overestimated.
In most experiments, we recorded, filtered, and digitized data, as
described previously (75), but in some experiments, we directly
acquired single-channel data to computer hard disk after filtering at a
corner frequency (fc) of 500 Hz using an eight-pole Bessel filter
(model F-900C/9L8L; Frequency Devices, Ottawa, IL) and digitizing
at a sampling rate of 5 kHz using a DigiData1320A interface (Mo-
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lecular Devices). To measure single-channel current amplitude (i),
Gaussian distributions were fit to current amplitude histograms, or
cursor measurements were used. For Po measurements, lists of open
and closed times were generated using a half-amplitude crossing
criterion for event detection and dwell time histograms constructed as
previously described (75); transitions 1 ms were excluded from the
analysis [8-pole Bessel filter rise time (T10–90) 	0.73 ms at fc  500
Hz]. Histograms were fitted with one or more component exponential
functions using the maximum likelihood method. For the purpose of
illustration, single-channel records were filtered at 500 Hz and digi-
tized at 5 kHz before file size compression by fivefold data reduction.
Reagents. PKA purified from bovine heart was purchased from
Calbiochem (Merck Chemicals, Nottingham, UK). Ivacaftor and lu-
macaftor were purchased from Selleck Chemicals (Stratech Scientific,
Newmarket, UK), while genistein was from LC Laboratories
(Woburn, MA) or Sigma-Aldrich (now Merck, Darmstadt, Germany).
Except for NPPB-AM (88), which was a generous gift of K. L. Kirk
and W. Wang (University of Alabama at Birmingham), other small
molecule CFTR modulators were generous gifts of the Cystic Fibrosis
Foundation CFTR Chemical Compound Distribution Program admin-
istered by R. J. Bridges (Rosalind Franklin University of Medicine
and Science). They included the CFTR correctors C1 [corr-3a (57)],
C2 [VRT-640 (66)], C3 [VRT-325 (84)], C4 [corr-4a (57)], C6
[corr-5c (57)], C9 [KM11060 (65)], C11 [Dynasore (49)], C12
[corr-2i (57)], C13 [corr-4c (57)], C14 [corr-4d (57)], C15 [corr-2b
(57)], C16 [corr-3d (57)], and C17 [15Jf (94)] and the CFTR poten-
tiators P1 [VRT-532 (84)], P2 [PG-01 (58)], P3 [SF-03 (58)], P4
[UCCF-853 (10)], P5 [
F508act-02 (93)], P7 [NS004 (33)], P8 [UCCF-
029 (76)], P9 [UCCF-180 (69)], and P10 [UCCF-152 (69)] (https://
on.cff.org/2HGbhVu). All other chemicals, including the pan-histone
deacetylase (HDAC) inhibitor and proteostasis regulator suberoylani-
lide hydroxamic acid (SAHA; Vorinostat), were of reagent grade and
supplied by Sigma-Aldrich (now Merck, Gillingham, UK).
Stock solutions of ATP were prepared in intracellular solution
directly before each experiment. Forskolin was dissolved in ethanol,
while CFTR modulators were solubilized in DMSO; all stock solu-
tions were stored at –20°C. Immediately before use, stock solutions
were diluted to final concentrations, and where necessary, the pH of
Fig. 1. The single-channel behavior of human and mouse wild-type (WT) and F508del-cystic fibrosis transmembrane conductance regulator (CFTR). A and B:
representative recordings of human and mouse wild-type and F508del-CFTR Cl channels in excised inside-out membrane patches from NIH-3T3 and Chinese
hamster ovary (CHO) cells heterologously expressing CFTR variants. Prior to study, the plasma membrane expression of human and mouse F508del-CFTR was
rescued by low-temperature incubation. The recordings were acquired at 37°C in the presence of ATP (1 mM) and PKA (75 nM) in the intracellular solution.
The closed-channel state (C), the subconductance state of mouse CFTR (O1), and the full open state [human (O), mouse (O2)] are indicated by dotted lines. Traces
on the left were filtered at 500 Hz, whereas the 1-s portions indicated by the bars shown on an expanded time scale to the right were filtered at 50 Hz. In this
and subsequent figures with single-channel data, a large Cl concentration gradient was imposed across excised membrane patches ([Cl]int, 147 mM; [Cl]ext,
10 mM), and membrane voltage was clamped at –50 mV. C and D: summary single-channel current amplitude (i) and open probability (Po) data for the full open
states of human and mouse CFTR determined from prolonged recordings (5 min) acquired from baby hamster kidney (BHK) and NIH-3T3 cells heterologously
expressing human CFTR and CHO cells heterologously expressing mouse CFTR using the conditions described in A and B before channel deactivation (human
F508del-CFTR). Dark gray and light gray circles represent individual values and columns means SE (human wild-type, n  6; human F508del-CFTR, n 
6; mouse wild type, n  6; mouse F508del-CFTR, n  18); *P  0.05 vs. human wild-type CFTR.
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the intracellular solution was readjusted to pH 7.3 to avoid pH-
dependent changes in CFTR function (15). Precautions against light-
sensitive reactions were observed when CFTR modulators were used.
DMSO was without effect on CFTR activity (70, 75). On completion
of experiments, the recording chamber was thoroughly cleaned before
reuse (91).
Statistics. Data recording and analyses were randomized, but not
blinded. Results are expressed as means SE of n observations, but
some group sizes were unequal due to technical difficulties with the
acquisition of single-channel data. All data were tested for normal
distribution using a Shapiro-Wilk normality test. To test for differ-
ences between two groups of data acquired within the same experi-
ment, we used Student’s paired t-test. To test for differences between
multiple groups of data, we used a one-way repeated-measures anal-
ysis of variance (ANOVA), followed by Dunnett’s multiple-compar-
ison test when a statistically significant difference was observed. Tests
were performed using SigmaPlot (version 13.0; Systat Software, San
Jose, CA) and GraphPad Prism 5 (San Diego, CA). Differences were
considered statistically significant when P  0.05. In iodide efflux
experiments (Figs. 8–11), n represents the number of monolayers of
cells, whereas in patch-clamp experiments (Figs. 1–7 and 12) n
represents the number of individual membrane patches obtained from
different cells. To avoid pseudo-replication, all experiments were
repeated at different times.
Data accessibility statement. Data are available at the University
of Bristol data repository, data.bris, at https://doi.org/10.5523/bris.
1xs4o58o3va0v23ytzulm4oo76.
RESULTS
In this study, we investigated the action of the F508del
mutation on mouse CFTR. Using cell-free membrane patches
from heterologous cells, we studied the single-channel behav-
ior and thermostability of human and mouse F508del-CFTR.
With the iodide efflux technique, we compared the rescue of
human and mouse F508del-CFTR function by CFTR modula-
tors. Unless otherwise indicated, all F508del-CFTR data were
acquired while channel activity was stable before channel
deactivation (51, 91).
The single-channel behavior of mouse F508del-CFTR. Fig-
ure 1 shows representative single-channel recordings and sum-
mary data of human and mouse CFTR in the absence and
presence of the F508del mutation following correction of its
processing defect by low-temperature incubation and channel
activation by PKA-dependent phosphorylation. Consistent
with previous results (46, 72), the single-channel behavior of
mouse wild-type CFTR differed from human wild-type CFTR
in two important respects. First, its single-channel current
amplitude was reduced 40% at –50 mV (Fig. 1, A–C). Second,
the gating pattern of mouse wild-type CFTR differed notice-
ably from human wild-type CFTR. For human wild-type
CFTR, channel gating is characterized by bursts of channel
openings to the full open state (O), interrupted by brief flickery
closures and separated by longer closures between bursts;
openings to subconductance states are rare for human wild-
type CFTR (Fig. 1A). By contrast, the gating behavior of
mouse wild-type CFTR is characterized by prolonged openings
to a low-amplitude subconductance state (O1), which is not
easily apparent without heavily filtering single-channel re-
cords, and many short-lived transitions to the full open state
(O2) (Fig. 1B). Figure 1D demonstrates that the Po of the full
open state of mouse wild-type CFTR was reduced 80% com-
pared with that of human wild-type CFTR. Because of the tiny
amplitude of the O1 state of mouse CFTR and the paucity of
excised inside-out membrane patches with only one active
mouse CFTR Cl channel, we did not quantify the i and Po of
the O1 state of mouse CFTR in this study.
Prior to channel deactivation (51), the pattern of channel
gating of human F508del-CFTR is characterized by infrequent
channel openings separated by very prolonged channel clo-
sures (Fig. 1A). By contrast, the gating pattern of mouse
F508del-CFTR resembled that of mouse wild-type CFTR with
many brief transitions to the O2 state superimposed upon pro-
longed openings of the O1 state (Fig. 1B). Figure 1D demonstrates
that the Po of the O2 state of mouse CFTR was unaffected by the
F508del mutation, whereas that of the full open state of human
CFTR was decreased 80% by the mutation. Similarly, Fig. 1C
reveals that the F508del mutation was without effect on current
Fig. 2. Thermostability of mouse F508del-cystic fibrosis transmembrane con-
ductance regulator (CFTR) in excised inside-out membrane patches A: repre-
sentative recordings of human and mouse F508del-CFTR in excised inside-out
membrane patches from baby hamster kidney (BHK) and Chinese hamster
ovary (CHO) cells heterologously expressing CFTR variants made in the
continuous presence of ATP (1 mM) and PKA (75 nM) once channel
activation was complete. Membrane patches were excised, and channels were
activated at 27°C to delay temperature-dependent channel deactivation. Only
after channels were fully activated was temperature increased to 37°C and
thermostability evaluated. Prior to study, the plasma membrane expression of
human and mouse F508del-CFTR was rescued by low-temperature incubation.
Arrows denote the closed-channel state, and downward deflections correspond
to channel openings. B and C: time courses of open probability (Po) for human
and mouse F508del-CFTR using the conditions described in A. Po values were
calculated for each 30-s interval. Data are means SE (human F508del-CFTR
heterologously expressed in BHK cells, n  10; mouse F508del-CFTR heterolo-
gously expressed in CHO cells, n 7). The human F508del-CFTR data in A and
C were originally published in Meng et al. (51).
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flow through the O2 state of mouse CFTR, like its effect on the i
of human CFTR. Thus, mouse CFTR has a different gating
pattern compared with human CFTR and it is unaffected by the
F508del mutation.
Mouse F508del-CFTR exhibits thermal stability at 37°C.
One characteristic of human F508del-CFTR is reduced protein
stability at the plasma membrane (48), which is evident in
single-channel records as accelerated channel rundown at 37°C
(71). Using excised inside-out membrane patches, we moni-
tored the duration of F508del-CFTR channel activity at 37°C
in the continuous presence of ATP and PKA by measuring Po
once channels were fully activated by PKA-dependent phos-
phorylation. A potential limitation of these studies is that
different cells were used to investigate the plasma membrane
stability of F508del-CFTR: BHK and NIH-3T3 cells for human
F508del-CFTR and CHO cells for mouse F508del-CFTR. In
contrast to human F508del-CFTR, which declines from Po
values of 	0.15 to zero within 8 min, the single-channel
activity of mouse F508del-CFTR was sustained; no loss of
channel activity was observed over the 10-min recordings (Fig.
2). In other experiments (n  5; data not shown), mouse
F508del-CFTR remained fully active in excised inside-out
membrane patches for 30 min at 37°C in the presence of
PKA and ATP in the intracellular solution. This behavior of
mouse F508del-CFTR differs noticeably from the thermal
instability of human F508del-CFTR in excised inside-out
membrane patches at 37°C (Fig. 2) (51, 91). We conclude that
the F508del mutation has reduced severity on the function of
mouse CFTR.
Differential responses of human and mouse CFTR to
ivacaftor. Some previous work using mammalian cells heter-
ologously expressing CFTR demonstrated that mouse CFTR is
unresponsive to certain agents, including ivacaftor, that poten-
tiate human CFTR (45, 72, 82). However, experiments using
Xenopus oocytes heterologously expressing CFTR studied at
22–23°C showed that mouse CFTR is potentiated by ivacaftor
(21, 22). To investigate further the ivacaftor-sensitivity of
mouse CFTR, we tested the acute effects of ivacaftor on human
and mouse wild-type and F508del-CFTR using excised inside-
out membrane patches. By applying the drug to the intracellu-
lar solution, we tested the direct effects of ivacaftor on the
single-channel activity of CFTR at 37°C.
Figure 3A shows representative recordings of mouse wild-
type CFTR in the absence and presence of ivacaftor (1 and 10
M), whereas Fig. 3B compares the response of human and
mouse wild-type CFTR to ivacaftor (10 nM to 10 M). Visual
inspection of single-channel recordings suggests that ivacaftor
(1 and 10 M) was without obvious effects on the O2 state of
mouse wild-type CFTR (Fig. 3A). Consistent with this idea,
there was no change in the Po of the O2 state of mouse
wild-type CFTR at all concentrations of ivacaftor tested (Fig.
3B). By contrast, ivacaftor (10 nM), the lowest concentration
tested, increased the Po of human wild-type CFTR by 49%,
after which it remained elevated at all further concentrations
tested (Fig. 3B).
Next, we tested the acute effects of ivacaftor (1 and 10 M)
on human and mouse F508del-CFTR in excised inside-out
membrane patches at 37°C. For these experiments, we rescued
Fig. 3. The effects of ivacaftor on the single-
channel behavior of mouse wild-type cystic
fibrosis transmembrane conductance regula-
tor (CFTR). A: representative recordings of
mouse wild-type CFTR in an excised inside-
out membrane patch from a Chinese hamster
ovary (CHO) cell heterologously expressing
CFTR in the absence and presence of the
indicated concentrations of ivacaftor added
acutely to the intracellular solution. The re-
cordings were acquired at 37°C in the con-
tinuous presence of ATP (1 mM) and PKA
(75 nM) in the intracellular solution. Dotted
lines indicate the closed-channel state, and
downward deflections correspond to channel
openings; the subconductance state of mouse
CFTR is not readily apparent in these re-
cordings. B: ivacaftor concentration-re-
sponse relationship for human and mouse
wild-type CFTR. Data are means  SE (hu-
man wild-type CFTR heterologously ex-
pressed in NIH-3T3 cells, n  3; mouse
wild-type CFTR heterologously expressed in
CHO cells, n  5); *P  0.05 vs. control.
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the plasma membrane expression of F508del-CFTR by either
low-temperature incubation or treatment with the CFTR cor-
rector lumacaftor. Figure 4 shows that ivacaftor (1 and 10 M)
was without clear effect on the single-channel activity of
mouse F508del-CFTR. The drug did not alter the Po of the O2
state of mouse F508del-CFTR (Fig. 4, C and F). The only
exception was a small, albeit significant (P  0.05), reduction
in the i of the O2 state of lumacaftor-rescued mouse F508del-
CFTR by ivacaftor (10 M) (Fig. 4E). By contrast, ivacaftor (1
and 10 M) potentiated human F508del-CFTR rescued by
either method, increasing Po by 97–551% without altering i
(Fig. 4, B, C, E, and F). Taken together, the data argue that
under the experimental conditions tested, ivacaftor potentiates
human, but not mouse, CFTR.
The effect of temperature on single-channel activity of
mouse CFTR. Toward an explanation for the different effects
of ivacaftor on mouse CFTR observed by Cui and colleagues
(21, 22) and ourselves, we reviewed the experimental condi-
tions employed to investigate mouse CFTR. One immediate
difference was temperature. Cui and colleagues (21, 22) re-
corded CFTR channel activity at 22–23°C, whereas we used
37°C. Therefore, we investigated the effect of temperature on
Fig. 4. The effects of ivacaftor on the single-
channel behavior of mouse F508del-cystic fi-
brosis transmembrane conductance regulator
(CFTR) rescued by low temperature or lu-
macaftor. A and D: representative recordings
of mouse F508del-CFTR in excised inside-out
membrane patches from Chinese hamster
ovary (CHO) cells heterologously expressing
CFTR in the absence and presence of the
indicated concentrations of ivacaftor added
acutely to the intracellular solution. Prior to
study, the plasma membrane expression of
mouse F508del-CFTR was rescued by either
low-temperature incubation (A) or treatment
with lumacaftor (VX-809; 3 M for 24 h at
37°C; D). The recordings were acquired at
37°C in the continuous presence of ATP (1
mM) and PKA (75 nM) in the intracellular
solution. Dotted lines indicate the closed-chan-
nel state, and downward deflections corre-
spond to channel openings; the subconduc-
tance state of mouse CFTR is not readily
apparent in these recordings. B, C, E, and F:
summary single-channel current amplitude (i;
B and E) and open probability (Po; C and F)
for the full open states of human and mouse
F508del-CFTR determined from prolonged re-
cordings (5 min) acquired from baby ham-
ster kidney (BHK) and NIH-3T3 cells heter-
ologously expressing human F508del-CFTR
and CHO cells heterologously expressing
mouse F508del-CFTR using the conditions de-
scribed in A and D before channel deactivation
(human F508del-CFTR). Dark gray and light
gray circles represent individual values and
columns means SE (B and C: human
F508del-CFTR, n  4–6; mouse F508del-
CFTR, n  8–10; E and F: human F508del-
CFTR, n  3–4; mouse F508del-CFTR, n 
5); *P  0.05 vs. control.
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the single-channel activity of mouse CFTR. Figure 5 shows
representative recordings of a single mouse F508del-CFTR
Cl channel at temperatures between 23 and 37°C, whereas
Fig. 6 quantifies the effects of temperature on current flow
through the O2 state and its activity for mouse wild-type and
F508del-CFTR.
Visual inspection of the single-channel records in Fig. 5
revealed that temperature has marked effects on the gating
behavior of mouse F508del-CFTR. At temperatures 30°C,
the frequency of opening to the O2 state was decreased notice-
ably, but their duration was prolonged markedly such that most
openings were to the full open state (Fig. 5A). By contrast, at
temperatures 30°C, the frequency of opening to the O2 state
was dramatically increased, but their duration was very brief,
with the result that many openings appeared truncated and did
not reach the amplitude of the full open state using the data
acquisition conditions that we employed (Fig. 5A). Interest-
ingly, openings of mouse F508del-CFTR to the O1 state were
observed at all temperatures tested (Fig. 5A). However, anal-
ysis of single-channel current amplitude histograms revealed
that the long closures separating openings to the O1 state were
prolonged at temperatures 30°C, but reduced in length at
temperatures 30°C, with the result that transitions to the O1
state dominated the histograms (Fig. 5B).
To quantify the effects of temperature on mouse CFTR, we
measured the i and Po of the O2 state. Figure 6A demonstrates
that current flow increased 45% from 23 to 37°C for both
human and mouse wild-type CFTR. Moreover, at all temper-
atures tested, the F508del mutation was without effect on
current flow through either human or mouse CFTR Cl chan-
nels in the full open state (Fig. 6A). We previously demon-
strated that human wild-type and F508del-CFTR exhibit strik-
ingly different relationships between temperature and Po (90).
For human wild-type CFTR, Po values increased progressively
between 23 and 37°C, whereas for human F508del-CFTR, the
relationship was bell-shaped, with a maximum Po value of
	30°C (Fig. 6B). For both mouse wild-type and F508del-
CFTR, Po values for the O2 state were comparable with those
of human F508del-CFTR at all temperatures tested (Fig. 6B).
Moreover, Po values for the O2 state of mouse wild-type CFTR
were independent of temperature, while those of the O2 state of
mouse F508del-CFTR increased only slightly, from 23 to 37°C
(Fig. 6B). We interpret these data to suggest that the temper-
ature dependence of Po for the full open state of mouse CFTR
is much less than that of human CFTR.
Potentiation of human wild-type and F508del-CFTR by
ivacaftor is temperature independent (90). Because Cui and
colleagues (21, 22) tested the action of ivacaftor on mouse
CFTR at 22–23°C, we examined the effects of ivacaftor on
mouse CFTR at different temperatures. Figure 7 shows repre-
sentative recordings of a single mouse F508del-CFTR Cl
channel in the presence of ivacaftor (100 nM) in the intracel-
Fig. 5. The temperature dependence of mouse F508del-cystic fibrosis transmembrane conductance regulator (CFTR) single-channel activity. A: representative
recordings of mouse F508del-CFTR Cl channels in an excised inside-out membrane patch from a Chinese hamster ovary (CHO) cell heterologously expressing
CFTR. Prior to study, the plasma membrane expression of mouse F508del-CFTR was rescued by low-temperature incubation. The recordings were acquired at
the indicated temperatures in the presence of ATP (1 mM) and PKA (75 nM) in the intracellular solution. Traces on the left were filtered at 500 Hz, whereas
the 2-s portions indicated by the bars shown on an expanded time scale to the right were filtered at 50 Hz. The closed-channel state (C), the subconductance
state of mouse CFTR (O1), and the full open state (O2) are indicated by dotted lines. B: single-channel current amplitude histograms for the 10-s traces shown
in A, filtered at 50 Hz, which removes transient events. Arrows denote C, O1, and O2.
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lular solution from 23 to 37°C and summary data from five
experiments. Visual inspection of the single-channel records in
Figs. 5A and 7A suggest that ivacaftor (100 nM) was without
effect on mouse F508del-CFTR channel gating. Neither open-
ings to the full open state (O2) nor to the tiny subconductance
state (O1) were increased. Consistent with these observations,
ivacaftor (100 nM) was without effect on the i and Po of the O2
state of mouse F508del-CFTR (Fig. 7, B and C).
Human and mouse F508del-CFTR have similar responses to
CFTR correctors, but different responses to CFTR potentiators.
To understand better the pharmacology of mouse F508del-
CFTR, we tested the effects of panels of small molecule CFTR
correctors and potentiators using the iodide efflux technique.
With this assay, we analyzed the behavior of a population of
mouse F508del-CFTR Cl channels in intact cells. Figures 8
and 9 show time courses of iodide efflux from CHO cells
heterologously expressing human and mouse F508del-CFTR,
respectively. Treatment of F508del-CFTR-expressing CHO
cells with the cAMP agonist forskolin (10 M) and the CFTR
potentiator genistein (50 M) elicited robust iodide efflux from
cells incubated with the CFTR corrector SAHA (3 M for 26
h at 37°C), a HDAC inhibitor and proteostasis regulator (38),
but not from cells treated with the vehicle DMSO (0.1%
vol/vol) (Figs. 8A and 9A). These data suggest that SAHA
rescues the plasma membrane expression of both human and
mouse F508del-CFTR. They confirm and extend previous
studies, which show SAHA rescue of human F508del-CFTR in
CFTR-overexpressing cell models (8, 38), but not in CF and
non-CF human nasal epithelial cells endogenously expressing
CFTR (8) nor in small intestinal tissue from F508del CF mice
(Bot AGM, Wilke M, and de Jonge HR, unpublished observa-
tions). Figure 10A demonstrates that 14 other CFTR correctors,
including the clinically approved small molecule lumacaftor,
also rescued both human and mouse F508del-CFTR. Although
the efficacy of different CFTR correctors varied considerably,
for any given compound, its action on human and mouse
F508del-CFTR was broadly similar. As a result, there was a
linear relationship between the action of CFTR correctors on
human and mouse F508del-CFTR (Fig. 11A).
Figure 8B demonstrates that following low-temperature in-
cubation, treatment of CHO cells expressing human F508del-
CFTR with forskolin (10 M) and either genistein (50 M) or
VRT-532 (P1; 10 M) (84) mediated robust iodide efflux,
whereas cells treated with forskolin and the vehicle DMSO
(0.1% vol/vol) generated little or none. Figure 9B shows time
courses of iodide efflux from CHO cells expressing mouse
F508del-CFTR treated with the same agents after low-temper-
ature incubation. Interestingly, genistein, but not VRT-532,
elicited robust iodide efflux from low-temperature-rescued
mouse F508del-CFTR (Fig. 9B). We interpret these results to
suggest that genistein, but not VRT-532, potentiates mouse
F508del-CFTR, whereas both agents potentiate human
F508del-CFTR. When we tested 11 other CFTR potentiators
on mouse F508del-CFTR, eight, including ivacaftor, were
without effect, but three [UCCF-029 (P8), UCCF-180 (P9) and
UCCF-152 (P10) (69, 76)] potentiated mouse F508del-CFTR,
albeit their efficacy was noticeably less than that of genistein
(Fig. 10B). Analysis of the effects of CFTR potentiators on
human and mouse F508del-CFTR revealed that there was no
relationship between the actions of compounds on human and
mouse F508del-CFTR, unlike the effects of CFTR correctors
(Fig. 11).
To understand better the action of genistein on mouse
F508del-CFTR, we studied single channels in excised inside-
out membrane patches from CHO cells expressing low-tem-
perature-rescued mouse F508del-CFTR. As a control, we stud-
ied low-temperature-rescued human F508del-CFTR in excised
inside-out membrane patches. Following the activation of hu-
man and mouse F508del-CFTR by PKA and ATP at 27°C, we
added genistein (20 M) to the intracellular solution. Once
channel potentiation was complete or 5 min had elapsed, we
increased temperature to 37°C and recorded channel activity
for a further 5 min. Figure 12, A and B, demonstrates that
genistein (20 M) potentiated human F508del-CFTR channel
gating, but was without effect on the O2 state of mouse
F508del-CFTR. Figure 12, C and D, reveals that genistein (20
M) was without effect on the i of human and mouse F508del-
CFTR and the Po of mouse F508del-CFTR, but increased the
Po of human F508del-CFTR by 170% at 27°C and by 210% at
37°C. Two independent investigators repeated this experiment
using genistein (50 M). Both found that genistein potentiated
human, but not mouse, F508del-CFTR (n  6; data not
shown). Taken together, the data suggest that the action of
genistein on mouse F508del-CFTR is mediated by a cytosolic
factor, which is lost on excision of inside-out membrane
patches. We conclude that CFTR correctors have similar ef-
fects on human and mouse F508del-CFTR, whereas most, but
not all, CFTR potentiators enhance the activity of human, but
not mouse, CFTR.
DISCUSSION
This study investigated the single-channel function and
pharmacology of mouse F508del-CFTR. In marked contrast to
the mutation’s action on human CFTR, F508del was without
effect on the gating behavior and thermostability of mouse
Fig. 6. Analysis of the temperature dependence of human and mouse wild-type
and F508del-cystic fibrosis transmembrane conductance regulator (CFTR) Cl
channels. A and B: summary data show the change in single-channel current
amplitude (i) and open probability (Po) between 23 and 37°C for the full open
states of human and mouse wild-type and F508del-CFTR. Data are from
inside-out membrane patches excised from baby hamster kidney (BHK) cells
heterologously expressing human CFTR and Chinese hamster ovary (CHO)
cells heterologously expressing mouse CFTR. Prior to study, human and
mouse F508del-CFTR were rescued by low-temperature incubation. Data are
means  SE (human wild-type CFTR, n  6–8; human F508del-CFTR, n 
4–8; mouse wild-type CFTR, n  4; mouse F508del-CFTR, n  10–12). In
A, the continuous lines are the fit of first-order regression functions to mean
data, whereas in B, they are the fit of second-order regression functions to
mean data. Note the break in the ordinate scale in B. The human wild-type and
F508del-CFTR data were originally published in Wang et al. (90).
L78 IVACAFTOR POTENTIATES HUMAN, BUT NOT MOUSE, F508del-CFTR
AJP-Lung Cell Mol Physiol • doi:10.1152/ajplung.00034.2019 • www.ajplung.org
Downloaded from www.physiology.org/journal/ajplung (086.090.011.159) on August 7, 2019.
CFTR. Moreover, the activity of mouse F508del-CFTR was
unaffected by most of the potentiators of human F508del-
CFTR tested, including ivacaftor.
Potential caveats of this study are the use of different cell
lines heterologously expressing CFTR variants and no control
of CFTR expression between different cells. Our rationale for
using different cell lines was to optimize the acquisition of
single-channel data. In previous work, we have demonstrated
that the single-channel behavior of human wild-type CFTR
(quantified by measuring i and Po) is equivalent when studied
in excised membrane patches from different mammalian cells
(15). The present study shows that this is also the case for
human F508del-CFTR. We have not studied mouse wild-type
or F508del-CFTR heterologously expressed in different cells.
But comparison of our own data (Refs. 46 and 72 and the
present study) with those of Ostedgaard et al. (55) suggest that
the single-channel behavior of mouse wild-type and F508del-
CFTR is comparable between CHO and HeLa cells. A further
limitation of our study is the use of CHO cells heterologously
expressing CFTR rather than airway epithelia endogenously
expressing CFTR. Encouragingly, comparison of the present
results with those of Cook et al. (20) demonstrate that ivacaftor
has similar effects on heterologously and endogenously ex-
pressed CFTR; human, but not mouse, CFTR is potentiated by
the small molecule.
The findings of the present study show some similarities, but
also some differences from previous studies of mouse CFTR.
In gallbladder epithelial cells, native mouse CFTR forms a
PKA- and ATP-regulated Cl-selective channel with a smaller
single-channel conductance than that of human CFTR (32).
Also consistent with the present results, the F508del mutation
was without effect on the Po of mouse CFTR (32). However,
native mouse CFTR in excised membrane patches from gall-
bladder epithelial cells opened more frequently to the full open
state than mouse CFTR heterologously expressed in CHO cells
(Ref. 32 and the present results).
When heterologously expressed in mammalian cells, mouse
CFTR exhibits a strikingly different pattern of channel gating
compared with human CFTR, predominantly residing in a tiny
subconductance state (O1), 	10% of the amplitude of the full
open state (O2), and only briefly transiting to O2 (Refs. 46, 55,
and 72 and the present results). However, when mouse CFTR
is heterologously expressed in Xenopus oocytes its gating
pattern is characterized by stochastic transitions to two sub-
conductance states and the full open state, with the amplitudes
of the subconductance states 	25 and 	65% of the full open
Fig. 7. The temperature dependence of mouse F508del-cystic fibrosis transmembrane conductance regulator (CFTR) treated with nanomolar concentrations of
ivacaftor. A: representative recordings of mouse F508del-CFTR Cl channels in an excised inside-out membrane patch from a Chinese hamster ovary (CHO)
cell heterologously expressing CFTR to show the effects of acute addition of ivacaftor (VX-770; 100 nM) to the intracellular solution. The recordings were
acquired at the indicated temperatures in the continuous presence of ATP (1 mM) and PKA (75 nM) in the intracellular solution. Prior to study, the plasma
membrane expression of mouse F508del-CFTR was rescued by low-temperature incubation. Traces on the left were filtered at 500 Hz, whereas the 2-s portions
indicated by the bars shown on an expanded time scale on the right were filtered at 50 Hz. The closed-channel state (C), the subconductance state of mouse CFTR
(O1), and the full open state (O2) are indicated by dotted lines. B and C: summary data show the change in single-channel current amplitude (i) and open
probability (Po) between 23 and 37°C for the full open state of mouse F508del-CFTR in membrane patches excised from CHO cells heterologously expressing
mouse F508del-CFTR. Data are means SE (control, n  10–12; VX-770, n  5). In B, the continuous lines are the fit of first-order regression functions to
mean data, whereas in C, they are the fit of second-order regression functions to mean data. In B and C, control data are the same as the mouse F508del-CFTR
data in Fig. 6.
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state; prolonged openings of the subconductance states are not
observed, and those of the full open state are 	66% shorter
than human CFTR (22). The present results reveal that differ-
ences in the temperature used to study mouse CFTR influence
its gating behavior. But this and other differences in experi-
mental conditions [e.g., membrane voltage and extracellular
Cl concentration (12)] are insufficient to explain the different
behavior of mouse CFTR in excised inside-out membrane
patches from mammalian cells and Xenopus oocytes (Refs. 22,
46, 55, and 72 and the present results). We do not attribute the
difference to the mouse CFTR cDNA because Scott-Ward et
al. (72) and Cui and McCarty (22) used the same supply of
cDNA. One possibility is the source of PKA used to phosphor-
ylate and activate mouse CFTR [Cui and McCarty (22), re-
combinant PKA; present results, PKA purified from bovine
heart]. However, an alternative or additional explanation might
be the different lipid compositions of mammalian cells and
Xenopus oocytes (54). Consistent with this idea, some previous
work argues that a subpopulation of CFTR molecules is re-
cruited to cholesterol-rich membrane microdomains (lipid
rafts) (1), and CFTR gating is regulated by membrane lipids (3,
61, 78). These explanations might also elucidate the different
gating behavior of native and heterologously expressed mouse
CFTR (Ref. 32 and the present results).
Previous work demonstrates that the severity of the F508del
processing defect is species dependent. Like human F508del-
CFTR (16), ferret and sheep F508del-CFTR fail to mature,
whereas mouse, pig, rabbit, and shark produce some mature
fully glycosylated protein (band C) and frog and chicken
substantially more (2, 31, 32, 55). Less is known about the
plasma membrane stability defect of F508del-CFTR across
species and cell type-dependent differences in the expression
of protein phosphatases, and other regulatory molecules poten-
tially confound interpretation of results. Nevertheless, the
Fig. 8. Genistein and VRT-532 potentiate iodide efflux by human F508del-
cystic fibrosis transmembrane conductance regulator (CFTR) rescued by low
temperature or the CFTR corrector suberoylanilide hydroxamic acid (SAHA).
A and B: time courses of iodide efflux from Chinese hamster ovary (CHO) cells
heterologously expressing human F508del-CFTR. In A, CHO cells were
pretreated with DMSO (0.1% vol/vol) or SAHA (3 M) for 26 h at 37°C
before study. In B, CHO cells were cultured at 26°C for 26 h before study.
During the periods indicated by the black bars, forskolin (10 M) and CFTR
potentiators [A: genistein (50 M); B: DMSO (0.1% vol/vol), genistein (50
M), or VRT-532 (10 M)] were added to the extracellular solution. Data are
means  SE (n  3).
Fig. 9. Genistein, but not VRT-532, potentiates iodide efflux by mouse
F508del-cystic fibrosis transmembrane conductance regulator (CFTR) rescued
by low temperature or the CFTR corrector suberoylanilide hydroxamic acid
(SAHA). A and B: time courses of iodide efflux from Chinese hamster ovary
(CHO) cells heterologously expressing mouse F508del-CFTR. In A, CHO cells
were pretreated with DMSO (0.1% vol/vol) or SAHA (3 M) for 26 h at 37°C
before study. In B, CHO cells were cultured at 26°C for 26 h before study.
During the periods indicated by the black bars, forskolin (10 M) and CFTR
potentiators [A: genistein (50 M); B: DMSO (0.1% vol/vol), genistein (50
M), or VRT-532 (1 or 10 M)] were added to the extracellular solution. Data
are means  SE (n  3).
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available data suggest a gradation of severity. In excised
membrane patches studied at 37°C, human F508del-CFTR
heterologously expressed in BHK and HEK cells demonstrates
marked thermoinstability, deactivating completely in 10 min
(89, 91), whereas sheep F508del-CFTR heterologously ex-
pressed in CHO cells requires 	15 min to deactivate com-
pletely, suggesting greater thermostability (11). Strikingly, the
present results show that mouse F508del-CFTR heterologously
expressed in CHO cells demonstrates thermostability at 37°C,
with no loss of single-channel activity observed in excised
membrane patches over a 10-min period. This behavior of
mouse F508del-CFTR is reminiscent of the single-channel
activity of chicken F508del-CFTR, which exhibited marked
thermostability at physiological temperatures when studied in
planar lipid bilayers (2).
In all species tested, the impact of the F508del mutation on
channel gating is noticeably less severe than for human CFTR
(reported reduction in Po: human, 80–89%; pig, 46%; chicken,
33%; sheep, 32%; and mouse, 0–50%; Refs. 2, 11, 32, and 55
and the present study). A likely explanation for the different
reductions in Po for mouse F508del-CFTR obtained by Ost-
edgaard et al. (55) and ourselves is the temperature used to
study CFTR channel gating. Figure 6 demonstrates that at
23°C, close to the temperature used by Ostedgaard et al. (55)
(25°C), the decrement in Po is 44% compared with 27% at
37°C. Except for French et al. (32) and the present study, visual
inspection of single-channel records reveals that the F508del
mutation slows the rate of channel opening with the result that
the interburst interval is prolonged in all species tested (2, 11,
55). These data argue that the F508del mutation disrupts the
formation of the NBD1:NBD2 dimer in the ATP-driven NBD
dimerization model of CFTR channel gating (86, 87). Building
on these data, Jih et al. (42) demonstrated that the F508del
mutation destabilized both the full and partial NBD1:NBD2
dimer configurations during CFTR channel gating. Taken to-
gether, the data suggest that structural differences between
CFTR orthologs account for the spectrum of effects of the
F508del mutation in CFTR processing, plasma membrane
stability, and channel gating.
To explain the difference in thermostability between chicken
and human F508del-CFTR, Aleksandrov et al. (2) searched for
and identified the F508del-CFTR revertant mutation I539T
(25, 36) and four proline residues located within dynamic
regions of NBD1 (S422P, S434P, S492P, and A534P). When
the I539T revertant and proline residues were introduced into
the human F508del-CFTR sequence, they restored CFTR pro-
cessing, thermostability, and channel gating (2), suggesting
that correction of NBD1 structure is sufficient to overcome the
misfolding of F508del-CFTR. However, residues S422, S492,
and A534 are conserved between human and mouse CFTR,
while the I539T revertant reduces the Po of mouse F508del-
CFTR (27). These data argue that other sequence changes
improve the gating behavior and thermostability of mouse
F508del-CFTR. Ostedgaard et al. (55) recognized that mouse
CFTR has only two of the four arginine-framed tripeptides
found in human CFTR, mutation of which allows F508del-
CFTR to traffic to the plasma membrane (14). Besides the
motifs located at R555 and R766, mouse CFTR has an addi-
tional arginine-framed tripeptide at R781 not found in human
CFTR (55). Building on these data, Dong et al. (27) used
human-murine CFTR chimeras to demonstrate that F508del-
CFTR maturation requires NBD1, whereas rescue of F508del-
CFTR channel gating necessitates NBD1-membrane-spanning
domain 2 (MSD2) interactions. These results support the idea
that optimal rescue of F508del-CFTR processing, stability, and
function requires correction of NBD1 folding and restoration
of NBD1-intracellular loop 4 (ICL4) interactions (50, 60).
They highlight how the consequences of the F508del mutation
are modified by the amino acid sequence of CFTR orthologs
and caution that sequence changes (e.g., I539T), which over-
come one defect (e.g., protein processing) might have undesir-
able effects on another defect (e.g., channel gating) (27).
Fig. 10. Comparison of the change in human and mouse F508del-cystic fibrosis
transmembrane conductance regulator (CFTR)-mediated iodide efflux elicited
by panels of CFTR correctors and potentiators. A and B: magnitude of
CFTR-mediated iodide efflux in Chinese hamster ovary (CHO) cells heterolo-
gously expressing human and mouse F508del-CFTR. CFTR-mediated iodide
efflux was quantified as magnitude of the initial increase in fractional 125I
efflux at 90 s, expressed as %/min. In A, CHO cells were pretreated with
DMSO (0.1% vol/vol) or the indicated CFTR correctors for 26 h at 37°C
before study, and CFTR-mediated iodide efflux was activated by forskolin (10
M) and potentiated by genistein (50 M). In B, CHO cells were cultured at
26°C for 26 h before study and CFTR-mediated iodide efflux was activated by
forskolin (10 M) and potentiated by the indicated CFTR potentiators. The
concentration of test CFTR correctors and potentiators used was optimized
with concentration-response relationships over a 100-fold concentration range
chosen around the most effective concentrations reported in the literature for
correction and potentiation of human F508del-CFTR. Data represent mean
values of two identical experiments, each performed in triplicate and expressed
as fold increase in CFTR activity relative to DMSO (0.1% vol/vol) alone. For
further details, see the text.
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Pedemonte et al. (59) demonstrated that cellular background
influences the rescue of human F508del-CFTR by CFTR cor-
rectors, but not CFTR potentiators. By contrast, the present
results reveal that in the case of human and mouse F508del-
CFTR the action of CFTR correctors is unaffected by species
differences, whereas that of CFTR potentiators is influenced
strongly. One notable exception is the CFTR potentiator
genistein, which enhanced the activity of both human and
Fig. 11. Differential responses of human and
mouse F508del-cystic fibrosis transmem-
brane conductance regulator (CFTR)-medi-
ated iodide efflux to CFTR potentiators, but
not correctors. A and B: relationship between
CFTR-mediated iodide efflux for human and
mouse F508del-CFTR heterologously ex-
pressed in Chinese hamster ovary (CHO)
cells and rescued by either CFTR correctors
or CFTR potentiators. Data are the fold in-
crease in CFTR activity relative to DMSO
(0.1% vol/vol) alone from Fig. 10. In A, the
continuous line is the fit of a first-order
regression function to the data (r2  0.88).
For further details, see the text.
Fig. 12. Genistein potentiates the single-channel activity of human, but not mouse, F508del-cystic fibrosis transmembrane conductance regulator (CFTR) in
excised inside-out membrane patches. A and B: representative recordings of human and mouse F508del-CFTR in excised inside-out membrane patches from baby
hamster kidney (BHK) and Chinese hamster ovary (CHO) cells heterologously expressing CFTR in the absence and presence of genistein (20 M) added acutely
to the intracellular solution. Prior to study, the plasma membrane expression of F508del-CFTR was rescued by low-temperature incubation. The recordings were
acquired at the indicated temperatures in the continuous presence of ATP (1 mM) and PKA (75 nM) in the intracellular solution. Dotted lines indicate the
closed-channel state, and downward deflections correspond to channel openings; the subconductance state of mouse CFTR is not readily apparent in these
recordings. C and D: summary single-channel current amplitude (i) and open probability (Po) for the full open states of human and mouse CFTR determined
from prolonged recordings (5 min) acquired from BHK cells heterologously expressing human F508del-CFTR and CHO cells heterologously expressing mouse
F508del-CFTR using the conditions described in A and B before channel deactivation (human F508del-CFTR). Dark gray and light gray circles represent
individual values and columns means SE (human F508del-CFTR, n  7–8; mouse F508del-CFTR, n  6–7); *P  0.05 vs. human F508del-CFTR control.
L82 IVACAFTOR POTENTIATES HUMAN, BUT NOT MOUSE, F508del-CFTR
AJP-Lung Cell Mol Physiol • doi:10.1152/ajplung.00034.2019 • www.ajplung.org
Downloaded from www.physiology.org/journal/ajplung (086.090.011.159) on August 7, 2019.
mouse F508del-CFTR in intact cells (Figs. 8B and 9B), but
only human F508del-CFTR in excised inside-out membrane
patches (Fig. 12). We interpret these data to suggest that the
effects of genistein on mouse F508del-CFTR in intact cells is
unlikely to result from its classical mode of action as a CFTR
potentiator (39). Because the action of genistein on mouse
F508del-CFTR is lost in cell-free membrane patches, we spec-
ulate that it acts indirectly, for example, by inhibiting the
endocytosis of F508del-CFTR, possibly linked to its role as a
tyrosine kinase inhibitor (47, 73).
Previous work has identified species-dependent differ-
ences in CFTR inhibition. For example, shark CFTR is
insensitive to the allosteric inhibitor CFTRinh-172, whereas
porcine CFTR is unaffected by the open-channel blocker
glibenclamide (44, 75, 77). To explain these cross-species
differences, Stahl et al. (77) proposed subtle differences in
CFTR structure and the local environment in the vicinity of
drug-binding sites. A similar explanation might account for
the different effects of ivacaftor on human and mouse CFTR
heterologously expressed in mammalian cells and Xenopus
oocytes (Refs. 21, 22, and 82 and the present results).
Ivacaftor accumulates in the inner leaflet of lipid bilayers
disrupting lipid rafts at high concentrations (5, 17), while
Xenopus oocytes have a distinct lipid composition to that of
mammalian cells (54). However, the different effects of
ivacaftor on heterologously expressed mouse CFTR in ex-
cised membrane patches and mouse models of autoimmune
disease (Ref. 96 and the present results) might require a
different explanation. One possibility is the action of iva-
caftor on the solute carriers (SLCs) SLC26A3, SLC26A9,
and SLC6A14, which modify CFTR function and hence,
disease severity in CF patients (17). Another might be the
different effects on mouse CFTR of acute and chronic
ivacaftor treatments (Refs. 20 and 96 and the present re-
sults). Future studies should address these possibilities.
In conclusion, the F508del mutation has distinct effects on
human and mouse CFTR (Table 1). The present results and
other data (32, 55) demonstrate that the severity of the F508del
mutation is greatly reduced in mouse CFTR. More mouse
F508del-CFTR protein is delivered to the plasma membrane,
where it exhibits notable thermostability and has little or no
adverse effects on channel gating compared with human
F508del-CFTR. The distinct effects of potentiators on human
and mouse CFTR suggest that, as for pyrophosphate (72),
human-mouse CFTR chimeras might be employed to investi-
gate the interaction of these small molecules with the CFTR
Cl channel. The data also suggest that CF mice have a role to
play in the evaluation of small molecules that rescue the
plasma membrane expression of F508del-CFTR, but not its
function as a regulated Cl channel, providing an impetus for
the development of humanized mouse models of CF to evalu-
ate new therapeutics (35). Thus, subtle differences in protein
structure between human and mouse CFTR strongly influence
the action of the F508del mutation and the response to small
molecule CFTR potentiators.
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